I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX SEQUENCE, Assistant Commissioner for Patents, Washington, D.C. 20231,

Accember 3

DX0804K

Atty. Docket No

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In re application of:

Christi L. PARHAM, et al.

Serial No.: 09/265,540

Filed: March 8, 1999

For: **HUMAN RECEPTOR PROTEINS:**

RELATED REAGENTS AND

METHODS

COMPUTER READABLE SEQUENCE

1643

not assigned

SUBMISSION

Examiner:

Art Unit:

Palo Alto, California 94304

BOX Sequence 5 Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

In reply to receipt of a "Notice to Comply" with requirements for patent applications containing nucleotide sequence and/or amino acid sequence 15 disclosures dated July 20, 2000, (paper no.9), for the above-identified application, in accordance with 37 CFR § 1.821 - 1.825, Applicants hereby submit: (1) a writeprotected diskette containing a computer-readable submission for the "Sequence Listing"; and (2) a "Sequence Listing" paper copy of the contents of the diskette.

REMARKS

Enclosed is a write protected floppy diskette with the sequence listing generated by the Patent Office's PATENTIN 2.0 program. The Diskette should comply with the requirements of 37 CFR §1.824 and is IBM PC compatible with a PC-DOS/MS-DOS operating system. If the diskette has been damaged, please call

10

20

25







TECH CENTER 1600/2900

Applicants and a replacement diskette will be provided. A hard paper copy printout of the diskette is attached thereto.

I hereby state the informational contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are believed to be the same. This submission introduces no new matter, since enclosed sequences are the same as sequences which were submitted in priority documents.

Applicants have invested over six hours of significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 CFR 1.135(c).

Applicants believe that no fees are required; however, if any fees are required by the present Response, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted.

25

5

10

15

20

Bv:

Sheela Mohan-Peterson Attorney for Applicants

Reg. No. 41,201

30

enclosures and attachments: one write-protected diskette (CRM) paper copy of contents of diskette

35

DNAX Research Institute 901 California Avenue

40 Palo Alto, California 94304-1104

Main: Direct: (650) 852-9196

(650) 496-1244

Fax:

(650) 496-1200